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Neoplasm in the vagina which occurs following treatment of cervical carcinoma could 
represent a separate primary neoplasm, a “field” response to a common carcinogen, or 
be due to neoplastic transformation of tissue from previous radiation treatment. Fifty 
patients with a second neoplasm in the vagina were identified: 17 following total hyster- 
ectomy for carcinoma in situ of cervix; 4 following radical hysterectomy; and 29 following 
radiotherapy for invasive cervical carcinoma. Their clinical features, diagnosis, and treat- 
ment modalities are presented. Since vaginal neoplasm may occur long after treatment of 
the initial cervical carcinoma especially after previous radiotherapy, life-long follow-up of 
all patients with cervical carcinoma is mandatory. 
INTRODUCTION 
Primary neoplasms that arise in the vagina are infrequent; preinvasive carci- 
noma of the vagina was an entity seldom identified until recently [ 11, while 
invasive carcinoma which constitutes less than 2% incidence [2-41 is ranked as 
the second rarest malignancy of the female genital tract. Increasing attention, 
however, has now been focused on neoplasms that arise in the vagina following 
the apparent cure of a cervical carcinoma. Such neoplasms have often in the 
past been regarded as residual or recurrent carcinoma. They are now recognized 
as a distinctive entity that may occur in various forms: (1) Following a total 
hysterectomy for in situ carcinoma of the cervix, as carcinoma in situ [5,6] or 
invasive carcinoma [7] of the vagina; (2) following radical hysterectomy for 
invasive carcinoma of the cervix, as carcinoma in situ or invasive carcinoma of 
the vagina [8]; and (3) following irradiation for invasive cervical carcinoma, as 
carcinoma in situ [9,10], invasive carcinoma [ 11,121, or sarcoma [ 131 of the 
vagina. This study is about a clinical analysis of a reasonably large number of 
such patients encountered in one institution and discusses their presentation, 
identification, and treatment. 
METHODS 
From the files of the Tumor Registry at the University of Michigan Hospital, 
3239 patients were found to have cervical carcinoma between January 1957 and 
January 1980. The case records of all patients who had a subsequent neoplasm 
in the vagina during this 23-year period were reviewed. Excluded from analysis 
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were patients whose diagnosis of an independent second primary neoplasm in 
the vagina could not be ascertained and those in whom the initial cervical car- 
cinoma had extended to the vagina on the hysterectomy specimen. Fifty patients 
with a second primary neoplasm in the vagina were thus identified, representing 
an incidence of 1.54% of patients who had cervical carcinoma. They all had a 
negative follow-up of at least a year, ranging from 1 to 39 years with a mean 
of 11.2 years. Other criteria employed in the identification of such cases include 
nonidentical histology between the two neoplasms and the presence of dysplasia 
in vaginal carcinoma in situ, or dysplasia and carcinoma in situ in invasive vaginal 
carcinoma suggesting their origin in the vagina rather than recurrent carcinoma. 
RESULTS 
Table 1 outlines the initial cervical carcinomas, their treatment, and the interval 
to the development of a second neoplasm in the vagina. It was noted that the 
mean age of patients who had in situ carcinoma of the cervix was 46.3 years 
and the mean interval to the development of carcinoma in situ and invasive 
carcinoma of the vagina was 5.8 and 12.6 years, respectively. On the other hand, 
the mean age of the patients who had invasive cervical carcinoma treated by 
irradiation was much younger (38.7 years), and their mean interval to the de- 
velopment of in situ and invasive neoplasms of the vagina was remarkably longer, 
at 9.9 and 22.7 years. 
The presentation of the vaginal neoplasms was found to bear no relationship 
to the initial type of cervical carcinoma or its treatment. Noteworthy was the 
finding that 28 of 31 patients (90.3%) with in situ and 8 of 19 patients (42.1%) 
TABLE 1 
SECOND PRIMARY NEOPLASMS OF THE VAGINA FOLLOWING CARCINOMA OF THE CERVIX 
Interval to vaginal neoplasm (years) 
1-5 6-10 >lO Total 
Prior total hysterectomy for CIS 
of cervix 
CIS of vagina 
Invasive carcinoma of vagina 
Total 
Prior radical hysterectomy for in- 
vasive carcinoma of cervix 
CIS of vagina 
Total 
Prior radiation for invasive carci- 
noma of cervix 
CIS of vagina 
Invasive carcinoma of vagina 
Sarcoma of vagina 
5 5 2 12 
1 0 4 5 
17 
1 2 1 4 
4 
2 7 6 15 
0 3 9 12 
0 0 2 2 
Total 29 
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TABLE 2 






Apex 29 12 
Upper lateral 2 5 
Midposterior - 1 
Distal anterior - 1 
Total 31 19 
with invasive vaginal neoplasm were asymptomatic. A red granular lesion was 
described in 15 of 31 patients (43.4%) with carcinoma in situ and 6 of 19 patients 
(31.6%) with invasive carcinoma of the vagina. Fourteen patients with in situ 
carcinoma were identified on the basis of an abnormal Pap smear alone. 
The locations of the vaginal neoplasms are as shown in Table 2. The most 
common site was the apex, followed by the lateral aspects of the upper vagina. 
One patient had the neoplasm located in the mid- and another, the distal vagina. 
Neoplasms in the cervix and vagina of dissimilar histology were found in three 
patients, all following irradiation. In one patient, the initial cervical carcinoma 
was adenocarcinoma while the vaginal carcinoma was squamous. In the other 
two patients, the cervical carcinoma was squamous while the vaginal neoplasm 
was sarcoma-one was carcinosarcoma and the other, fibrosarcoma; both oc- 
curred 13 years after irradiation for cervical carcinoma. 
Significantly, most of the invasive carcinomas that arose in the vagina were 
Stage I lesions. Of the 18 patients with invasive carcinoma of the vagina following 
carcinoma in situ or invasive carcinoma of the cervix, only 8 (27.8%) had ex- 
tension beyond the vagina, and in 2 patients the neoplasm had infiltrated the 
pelvic side wall. 
The treatment modalities for the 31 patients with carcinoma in situ of the 
vagina are as shown in Table 3. The most common treatment was vaginectomy 
TABLE 3 
TREATMENT AND STATUS OF PATIENTS WITH CIS OF VAGINA FOLLOWING CERVICAL CARCINOMA 
No. Status 
Vaginectomy 24 NED 22 (8 months-18 years); 1 died of recurrent 
invasive Ca of vagina; 1 died of intercurrent 
disease 
TAHBSO and vaginectomy 4 NED (l-6 years) 
RH, PLND, and vaginectomy 1 NED (6 years) 
Vaginal radium 2 NED (6-7 years) 
Note. TAHBSO, total abdominal hysterectomy and bilateral salpingo-oophorectomy; RH,PLND, 
radical hysterectomy and pelvic lymphadenectomy. 
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which was performed in 24 patients-20 partial and 4 total, and 5 patients had 
simultaneous vaginoplasty with split thickness skin graft as well. The availability 
of additional surgical tissue led to an unexpected diagnosis of superficial invasion 
in 4 of these patients. A total hysterectomy, bilateral salpingo-oophorectomy, 
and upper vaginectomy were performed on 4 patients who previously had ir- 
radiation for an invasive cervical carcinoma. One patient underwent radical 
hysterectomy, pelvic lymphadenectomy, and total vaginectomy when the original 
biopsy showed questionable “microinvasion.” Two patients were treated with 
vaginal radium. One follow-up examination, 1 patient was noted to have recurrent 
carcinoma in situ of the vagina and she was treated with further excision. Two 
patients died-l from unrelated disease and the other from progressive disease 
2 years following partial vaginectomy for incidental superficial invasive disease. 
Table 4 shows the treatment for patients with invasive neoplasms of the vagina. 
Irradiation was carried out on all five patients with invasive vaginal carcinoma 
following total hysterectomy for in situ carcinoma of the cervix; only two are 
alive at 3 and 6 years. Radiation was also given to five other patients who 
previously had irradiation for invasive carcinoma of the cervix; three died within 
a year, while the fourth sustained numerous episodes of bowel fistulae requiring 
multiple corrective surgery and died without disease 3 years later. The lone 
survivor is disease free for 8 months. Five patients underwent total pelvic ex- 
enteration; one died of postoperative sepsis, the rest are alive from 6 months 
to 7 years. Three patients with supeficial invasive disease underwent radical 
vaginectomy; one died of progressive disease within a year and one is alive for 
5 years. The third patient is of interest in that she developed a superficially 
invasive carcinoma on the vaginectomy skin graft 7 years later and was further 
treated by an exenteration. 
That such patients may be prone to other neoplasms was demonstrated in four 
patients. Two patients had vulvar carcinoma in situ that occurred synchronously 
with vaginal carcinoma in situ. One patient, in a 1Zyear interim period between 
an invasive cervical carcinoma and an in situ vaginal carcinoma, developed a 
breast carcinoma and a meningioma, both successfully treated. The fourth patient 
had five independent neoplasms over a span of 17 years. In sequence, they are 
carcinoma in situ of the cervix, carcinoma in situ of the vagina, hemangioblastoma 
TABLE 4 
TREATMENT AND STATUS OF PATIENTS WITH INVASIVE PRIMARY NEOPLASM ,OF THE VAGINA FOLLOWING 
CERVICAL CARCINOMA 
No. status 
Radical vaginectomy 3 1 died of progressive disease; 1 recurrent CIS treated by 
local excision; 1 recurrence treated by exenteration 
Total pelvic exenteration 5 NED 4 (6 months-6 years); 1 died of postoperative sepsis 
Radiation” 10 NED 4 (6 months-6 years); 6 died of disease 
Chemotherapy 1 Died of disease 
’ Five patients had prior irradiation. 
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of the cerebellum, carcinoma of the breast, and invasive carcinoma of the vulva; 
she died of her last acquired neoplasm. 
DISCUSSION 
When carcinoma of the vagina occurs following carcinoma of the cervix, the 
question frequently raised is whether it is a residual or recurrent carcinoma, or 
represents a new primary lesion. Their distinction, though not always clear cut, 
is nevertheless possible. 
In situ carcinoma of the vagina is rare without a preceding or synchronous 
carcinoma in the cervix [5,6,9]. The reported incidence of “recurrent” carcinoma 
in situ following hysterectomy for carcinoma in situ of the cervix ranged from 
0.7 to 6.6% 114-161. A preoperative mapping of the lesion in a patient with 
carcinoma of the cervix should be a prerequisite in order to exclude extension 
of the lesion on to the vagina or the presence of multicentric carcinoma of the 
cervix and vagina. When the initial cervical lesion is completely extirpated as 
determined by pathological examination of the specimen and following a period 
of negative follow-up examinations, any lesion that appears in the vagina must 
be considered a new primary lesion. 
Invasive vaginal carcinoma that arises long after a total hysterectomy for in 
situ carcinoma of the cervix has been considered a curious entity [7,16,17]. 
Coppleson [17] thought that some of these patients originally might have an 
invasive cervical carcinoma that extended into the vagina. The late occurrence 
of this cancer after a mean interval of 12.6 years in our five patients suggests 
that it is an independent neoplasm. 
Carcinoma in situ and primary invasive vaginal carcinoma following radical 
hysterectomy for invasive carcinoma of the cervix have rarely been reported. 
Kanbour {8] documented five such patients with in situ and four with invasive 
carcinoma. We identified only four patients with in situ carcinoma and two among 
them received adjunctive postoperative irradiation as well. No patients were 
found to have a primary invasive vaginal carcinoma when recurrent invasive 
cervical carcinoma was excluded. It is generally accepted that 5-year survival 
following treatment of invasive cervical carcinoma is an accurate measure of 
curability [18]. Therefore, an invasive vaginal carcinoma that arises more than 
5 years after radical hysterectomy for invasive cervical carcinoma should lead 
to a strong suspicion of a possible new lesion. It is likely that the removal of 
the upper half of the vagina may also remove the site at risk for carcinoma in 
the vagina, considering the fact that the cervix and the upper vagina are of 
Mullerian origin and they provide a common embryological field that can be 
acted upon by a common carcinogen. 
Neoplasms arising in the vagina following irradiation may suggest radiation 
carcinogenicity. This is evidenced by such neoplasms occurring long after ir- 
radiation, many of them possessing histological features suggestive of de now 
origin when concomitant dysplasia and carcinoma in situ are also found [19-211. 
The implication of radiation carcinogenicity is especially strong in our patients. 
Twenty-seven of twenty-nine patients (93.1%) developed a neoplasm in the vagina 
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more than 5 years, and 17 of them (58.6%) more than 10 years after irradiation 
(Table 1). Noted also were 2 patients who developed sarcoma of the vagina 
following radiotherapy. Sarcoma arising in the irradiated soft tissue and bone 
have been well documented in the literature [22,231. Furthermore, 8 of 15 patients 
(53.3%) with carcinoma in situ of the vagina had associated dysplasia, and 7 of 
12 patients (58.3%) with invasive squamous carcinoma of the vagina demonstrated 
dysplasia and carcinoma in situ as well. 
The observation in this study that young patients irradiated for invasive cervical 
carcinoma are at risk of developing a second neoplasm in the vagina warrants 
attention. Eight of twenty-nine patients were below the age of 35 when they 
received radiotherapy for their cervical cancer. Such an observation was first 
reported by Barrie and Brunschwig [24] in 1970. They found 9 of 11 patients in 
their 20s or 30s when irradiated for their cervical carcinoma, subsequently 
developed a second cancer in the cervix 15 to 39 years later. Futoran and Nolan 
[13] also reported a series of 76 patients 38 years of age or younger, 12 of whom 
subsequently developed carcinoma in the vagina following irradiation for their 
cervical cancer. These young patients live long enough to develop a second 
neoplasm in the irradiated vagina, thus life-long surveillance in this unique group 
of patients is mandatory. 
While invasive neoplasm in the vagina is frequently evident on examination, 
that of in situ carcinoma often is obscure. The presence of a “pink blush,” as 
described by Young [25] to be characteristic of carcinoma in situ of the vagina, 
should arouse suspicion. Vaginal cytology is undoubtedly useful; misinterpre- 
tation can, however, occur in the presence of extreme atrophy or radiation 
atypia. Colposcopic examination of the vagina may also at times be nonproductive 
as the lesion may not be delineated owing to radiation atrophy. In such a situation, 
a 2-week course of topical or oral estrogen will often help to outline the lesion. 
Particular attention should be directed to the angles of the apex of vagina as 
they are often the hidden sites of carcinoma and such areas are difficult to 
examine and biopsy. 
The treatment of vaginal neoplasms should be individualized, taking into con- 
sideration the patient’s age, type of malignancy, extent of disease, previous 
therapy, and the need to preserve sexual function. Although some may find 
topical application of 5 FU more acceptable in carcinoma in situ of the vagina 
[26], our preference is vaginectomy. A limited partial vaginectomy or an excision 
can be performed following colposcopic mapping. Vaginal obliteration or stenosis 
can be avoided by a vaginoplasty or the use of vaginal dilator alone. Its important 
advantage lies in the availability of additional tissue for diagnosis lest a superficial 
or frank invasive carcinoma should be missed. Vaginal radium is also an equally 
effective method for treating carcinoma in situ of the vagina especially if the 
carcinoma is multicentric. Other conservative methods such as immunotherapy 
with DNCB [27] and laser treatment 1281 are still experimental. In patients who 
have invasive neoplasm of the vagina, the choice is one of radical surgery or 
exenteration in patients who have previously been irradiated, or primary irra- 
diation in patients who previously had surgery for the cervical carcinoma. Reir- 
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radiation for cure, no matter how long the interim period may be, is ineffective 
and fraught with potential complications and is not recommended. 
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